Drug General Information (ID: DDIBOR61D0)
Drug Name			Papaverine		Drug Info		Maraviroc		Drug Info
Drug Type		Small molecule				Small molecule
Therapeutic Class		Vasodilator Agents				Anti-Hiv Agents
Structure

Mechanism of Papaverine-Maraviroc Interaction (Severity Level: Moderate)
Additive hypotensive effects Click to Show/Hide Mechanism Graph
Drug Name		Papaverine				Maraviroc
Mechanism 1		Hypotensive effects Phosphodiesterase 4D/5A  Inhibitor				Antihypertensive agent
Key Mechanism Factor 1
		Factor Name		Phosphodiesterase				Structure Sequence
		Protein Family		Cyclic nucleotide phosphodiesterase family
		Protein Function		Hydrolyzes the second messenger cAMP, which is a key regulator of many important physiological processes.     Click to Show/Hide
Mechanism Description		Additive hypotensive effects by the combination of Papaverine and Maraviroc
Mechanism 2		Hypotensive effects Phosphodiesterase 4D/5A  Inhibitor				Hypotensive effects
Key Mechanism Factor 2
		Factor Name		Phosphodiesterase				Structure Sequence
		Protein Family		Cyclic nucleotide phosphodiesterase family
		Protein Function		Hydrolyzes the second messenger cAMP, which is a key regulator of many important physiological processes.     Click to Show/Hide
Mechanism Description		Additive hypotensive effects by the combination of Papaverine and Maraviroc

Recommended Action
Management		Caution is advised when maraviroc is prescribed to patients on concomitant medications known to lower blood pressure. Close monitoring for development of hypotension is recommended. Ambulatory patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their doctor if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.

References
1	Product Information. Selzentry (maraviroc). Pfizer U.S. Pharmaceuticals Group, New York, NY.